Company intelligence / Profile preview

Oxford GlycoSciences

Oxford, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

Oxford GlycoSciences developed a proteomics platform and brought Zavesca (miglustat), a treatment for Gaucher disease, to market. The company also established collaborations with multinational pharmaceutical companies. It was acquired by Celltech in 2003 after a competitive bidding process involving several biotech firms. At the time of acquisition, its main commercial product was Zavesca, and it had ongoing research programs in proteomics and cancer targets[2][3][8].

Therapeutic areas: OncologyRare Diseases
Modalities: Proteomics-based drug discoverysmall moleculesbiologicsglycobiology
Industry: Biotech

Partnerships

Collaborations with several multinational pharmaceutical companies for proteomics applicationsActelion discussed as potential partner/licensee for rights to Zavesca after Celltech’s acquisition

Beyond the preview

Go deeper on Oxford GlycoSciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oxford GlycoSciences.